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Abstract
Retinopathy of prematurity (ROP) is a vascular vitreoretinopathy that affects infants with short gestational age and
low birth-weight. The condition is a multifactorial disease and is clinically similar to familial exudative vitreoretino-
pathy (FEVR), which is a bilateral hereditary eye disorder affecting full-term infants. Both of them are characterized
by the abnormal vessel growth in the vitreous that can lead to vitreoretinal traction, retinal detachment and other
complications resulting in blindness. Despite the recent advances in diagnosis and treatment, ROP remains a major
cause of childhood blindness in developed countries. The etiology of pathogenesis of advanced ROP is currently
unknown. In the past, many causative factors such as length of time exposed to supplemental oxygen, excessive
ambient light exposure and hypoxia have been suggested but evidence for these as independent risk factors in
recent years is not compelling. It is not clear why ROP in a subset of infants with low birth-weight progresses to a
severe stage (retinal detachment) despite timely intervention whereas in other infants with similar clinical charac-
teristics ROP regresses spontaneously. Recent research with candidate gene approach, higher concordance rate in
monozygotic twins and other clinical and experimental animal studies, suggest a strong genetic predisposition to
ROP besides environmental factors such as prematurity. Three genes, which are involved in the Wnt signaling path-
way, are mutated in both FEVR and in a small percentage of ROP disorder. However, none of the genetic factors
identified thus far in ROP, account for a substantial number of patient population. Future studies involving
genomics, bioinformatics and proteomics may provide a better understanding of the pathophysiology and
management of ROP.
Introduction
Retinopathy of prematurity (ROP), also known as retro-
lental fibroplasia, is a well-known visual impairment in
premature children. It is a disease of developing retinal
blood vessels, which is seen predominantly in infants of
short gestational age and low birth-weight. The condi-
tion is a multifactorial disease and is clinically similar to
familial exudative vitreoretinopathy (FEVR), which is a
bilateral hereditary eye disorder affecting full-term
infant. While FEVR is a genetically heterogeneous disor-
der and is inherited as an X-linked recessive, autosomal
dominant (AD) and autosomal recessive (AR) mode [1],
ROP is a non-familial disorder. Both of these disorders
cause blindness in young children and are characterized
in the early stage by the premature arrest of the vascu-
larization of the peripheral retina (Fig. 1) that can lead
to extra-retinal fibrovascular proliferation, vitreal
traction, retinal fold and retinal detachment resulting in
blindness. Both of them carry a high financial cost for
the community and the individual by affecting the nor-
mal motor, language, conceptual and social development
of the child. It is estimated that the overall incidence
rate of the condition is about 68% among infants born
with birth weight less than 1251 g and 98% among
children born with birth weight less than 750 g [2].
Pathogenesis
The International Classification of ROP divides the
development of the disorder into 5 stages. In the early
stages, ROP is characterized by an incomplete vasculari-
zation of the retina (Fig. 1 panel A), with a sharply
demarcated boundary between vascularized and avascu-
larized retina (stage 1). This can progress to an elevated
ridge (Fig. 1 panel B) that consists of mesenchymal tis-
sue (stage 2). In more advanced stages of the disease,
extra-retinal fibrovascular proliferation occurs (Fig. 1
panel C) on the posterior border of the ridge (stage 3)
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any medium, provided the original work is properly cited.Figure 1 A schematic illustration of some of the abnormalities associated with advanced ROP. In the early stages, ROP is characterized by
an incomplete vascularization of the peripheral retina (panel A), with a sharply demarcated boundary between vascularized and avascularized
retina (stage 1). This can progress to an elevated ridge (panel B) that consists of mesenchymal tissue (stage 2). In more advanced stages of the
disease, extra-retinal fibrovascular proliferation occurs (panel C) on the posterior border of the ridge (stage 3). In addition to the abnormal
vascularization, the normal gelatinous vitreous (panel D) becomes partially liquefied (panel E). While spontaneous regression often occurs, an
organization and contraction of vitreous collagen can take place (panel E) which can lead to a retinal fold (panel F) causing partial (panel G) or
total retinal detachment (panel H) that represent stages 4 and 5 respectively.
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vessels (stage 3+ or threshold). In addition to the abnor-
mal vascularization, the normal gelatinous vitreous
(Fig. 1 panel D) becomes partially liquefied (Fig. 1 panel
E). While spontaneous regression often occurs, an orga-
nization and contraction of vitreous collagen can take
place (Fig. 1 panels D, E and F) leading to partial (stage
4) or total (stage 5) retinal detachment (Fig. 1 panels G
and H respectively). In advanced ROP, abnormal vessels
grow out of the retina into the vitreous. This abnormal
growth can lead to hemorrhage, fibrovascular changes,
vitreoretinal traction, and retinal detachment (Fig. 1)
and ultimately results in blindness.
Additionally, other complications of ROP or current
treatment have also been reported. This includes retinal
fold, dragging of the macula, glaucoma, cataract and
strabismus. It is a life time disease. The condition in
some children may appear milder and may not require
treatment during the active stages or it may be regressed
with little or no loss of visual function. However, these
same children may later develop visual impairments
from progressive retinal epithelial changes [3,4]. This
type of childhood blindness has severe consequences
that may result in less opportunity for education,
employment and earning potential. It can also affect
socioeconomic development.
Genetic risk factors
Despite advances in our understanding and management
of ROP, it remains a leading cause of blindness in children
in developed countries. Although many causative factors
such as excessive light exposure, length of time exposed to
supplemental oxygen and hypoxia have been suggested
[5,6], the etiology of pathogenesis of advanced ROP is not
understood. However, low birth-weight and short gesta-
tional age have been consistently shown to be associated
with ROP. It is unclear why ROP in a subset of infants
with low birth-weight progresses to a severe stage despite
timely intervention whereas in other infants with similar
clinical characteristics, ROP regresses spontaneously.
Molecular genetic studies of FEVR have identified four
causative genes to date (NDP, FZD4, LRP5 and
TSPAN12) which when mutated cause X-linked, AD and
AR FEVR (also some sporadic cases). All of these genes
are involved in the beta-catenin mediated Wnt signaling
pathway (see below) that controls the development of the
retinal vasculature [7-9]. Because of mutations in these
genes, norrin-FZD4-LRP5-TSPAN12 signaling pathway
may become defective and that may produce abnormal
vascularization giving rise to FEVR pathology. Interest-
ingly, using a candidate gene approach, it has been shown
that at least three of the four FEVR genes (NDP, FZD4
and LRP5) are also mutated in a small percentage (3-11%)
of severe ROP patients [[10-19] and Hiraoka etal. personal
communication]. This genetic predisposition is further
supported by the recent twin studies [20], race [21] and
strain-dependent differences in oxygen induced ROP in
the inbred rats [22-24]. Because three of the four FEVR
genes are mutated in advanced ROP and all four FEVR
genes are involved in Wnt signaling pathway, the above
genetic explanation of ROP supports a role for the Wnt
signaling pathway in the development of severe ROP that
can be of a therapeutic value in the future. Because it is
the same pathway that appears to be defective in both of
these disorders (ROP and FEVR), their clinical similarities
can be explained. Considering all the available data to
date, it appears that NDP, FZD4 and LRP5 gene poly-
morphisms can account for about 10-12% of ROP and this
prevalence may be correlated with ethnic differences.
However, the NDP, FZD4 and LRP5 genes are not the
major genes independently accounting for a significant
portion of ROP patients. This suggests that mutations in
other genes involved in retinal development, angiogenesis
and Wnt signaling pathway could also be associated with
severe ROP in a small proportion of patients.
Association of other genes with ROP
The blinding complication of ROP is strongly associated
with the development of retinal neovascularization. In
normal instances, the vascularization of the human
r e t i n ai sl a r g e l yc o m p l e t eb yt h e4
th month of gestation
but peripheral retinal vascularization will not be in place
until the fetus is near term. ROP pathogenesis occurs in
two phases: the vascular attenuation phase (phase I) and
the fibrovascular proliferative phase (phase II). In phase
I, hyperoxia (because of supplemental oxygen) causes
cessation of normal retinal vascularization and in phase
II, hypoxia renews vascularization. In both of these cases
vascular endothelial growth factor (VEGF) plays a major
role [25,26] and depending on local retinal responses,
the effect can be normal or abnormal vascularization.
Several case control studies have also confirmed the
association of VEGF single nucleotide polymorphisms
(SNPs) with diseases as diverse as breast cancer, oral
cancer, Alzheimer disease and kidney disease. It has also
been reported that increased expression of VEGF gene
is associated with both avascular retina and intravitreous
neovascularization [27] in a model of ROP. Many poly-
morphisms of VEGF gene have been described. Some of
them are in the promoter and 5′-untranslated region
but some of them are in the 3′-untranslated region
(3′-UTR). Several polymorphisms within the VEGF gene
are correlated with variation in VEGF protein produc-
tion [28]. For instance, it was reported previously [29]
that the CC genotype of C936T polymorphism in the
3′-UTR of VEGF gene was associated with an increase
in the VEGF level in the peripheral blood circulation as
compared with CT and TT genotypes. In support of the
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shown an association of VEGF gene polymorphism and
ROP [30,31] but these results are not replicated by
other studies [32-36].
Additionally, it has also been reported that a pro-
longed period of low levels of insulin-like growth factor-
I (IGF-I) may predict the development of ROP and
other complications of premature birth [37]. Infants
with higher IGF-I do not develop ROP and exhibit bet-
ter vascular development. This growth factor (IGF-I) is
an intrauterine growth factor and is expressed in retinal
cells. Several studies also suggest that it is essential for
vascular development of the eye in the postnatal period.
These results were supported by IGF-I knockout mice
that developed abnormal retinal vascular growth.
Because prematurity is one of the factors that contri-
butes to ROP and the IGF-I level is determined by the
IGF-I receptor (IGF-I R) and the most prevalent poly-
morphism of IGF-I R (3174 G to A) exhibited low levels
of free plasma IGF-I, it is possible that it may have a
role in ROP. However, studies [38,39] do not support
the association of this polymorphism and the risk of
advanced ROP in different populations. Similarly, angio-
tensin-converting enzyme gene polymorphism is found
to be associated with ROP in Kuwaiti population [16]
but not in the other population [40,41]. Additionally,
suggestive association has been reported between
AGTR1 (encodes angiotensin II type I receptor), IHH
(Indian Hedgehog), TBX-5 (T-box 5), glycoprotein Ib
alpha polypeptide (GP1BA) and cholesterol ester trans-
fer protein (CETP) and development of ROP [42]. How-
ever, these results need to be confirmed in a larger and
independent population.
Relationship between FEVR and advanced ROP
While it remains to be seen whether the recently
reported fourth gene (TSPAN12) of FEVR is also
involved in advanced ROP patients, the above studies
demonstrated that mutations are present in either small
percentage of ROP patients or limited geographically to
as p e c i f i ce t h n i cp o p u l a t i o n .A l t h o u g ht h e r ea r em a n y
questions such as accuracy of diagnosis and small per-
centage of ROP patients harboring mutations in FEVR
genes that need to be addressed before any conclusion
can be drawn, based on the studies conducted from
around the world involving different ethnic background
patients, it is possible that the advanced ROP could be
in fact a sporadic FEVR and the prematurity is an envir-
onmental factor that simply speeds up the progression
of the disease. Thus, it is conceivable that in ROP, gene
abnormality coupled with postnatal physiological
changes and various environmental factors (e.g. prema-
turity) may result in the development and progression
of ROP that would ordinarily be suppressed in a full
term infant with FEVR. Based on these assumptions we
propose the following (Fig. 2), purely speculative, dou-
ble-hit-working model to explain the development of
advanced ROP in premature infants. In stage 4 - 5 ROP,
de novo gene mutation coupled with environmental fac-
tors (e.g. prematurity) may lead to the progression and
development of retinal detachment whereas prematurity
alone without gene mutation may lead to an early stage
of ROP that may subsequently regress to a normal con-
dition. On the other hand, inherited or de novo muta-
tions without prematurity may result in familial and
sporadic FEVR respectively, which develop during the
first decade of life.
Wnt signaling pathway
The exact mechanism to explain how the mutant genes
thus far identified cause incomplete vascularization of
the retina in ROP is not known. However, mutations in
the NDP, FZD4 and LRP5 genes in ROP and the finding
that the same genes are also mutated in a morphologi-
cally similar disorder FEVR suggest that a similar
mechanism may be involved in ROP and FEVR patho-
genesis. Interestingly, as mentioned above, all the above
four genes are involved in the Wnt signaling pathway.
Therefore, the defective Wnt signaling pathway may be
responsible for both FEVR and ROP pathogenesis. The
Wnt signaling pathway (Fig. 3) is highly conserved and
regulated among many species. It plays a key role in
embryonic development including eye development. It
was also shown that TSPAN12 is a component of the
norrin -FZD4 - LRP5 - signaling complex and increases
the levels of norrin-beta-catenin signaling but not Wnt-
beta-catenin signaling. The protein TSPAN 12 is a
member of tetraspanin family and facilitates the forma-
tion of multimolecular membrane complexes. A series
of experiments demonstrated that TSPAN 12 is required
for the multimerization of FZD4. Recently, it has been
reported that [43] a transcription factor called sox 17 is
upregulated by norrin-FZD4-LRP5 signaling. This factor
plays an important role in inducing the angiogenic pro-
gram for retinal vascularization. Therefore, loss of or
insufficient norrin-FZD4-LRP5 signaling (due to muta-
tions) may cause defective vascular growth and that may
lead to retinal hypovascularization, which is the predo-
minant feature of both FEVR and ROP. Although there
is no direct correlation between genotype and pheno-
type, alterations in highly conserved amino acids may
affect the structure of receptors (FZD4 and LRP5),
ligand (NDP), localization of mRNA or proteins or the
quantity of proteins. This may inactivate or alter the
pathway resulting in the inhibition or abnormality of
vascular development in the above disorders. Mutations
in the 5′ and 3′-untranslated regions (seen in NDP gene
in ROP patients) may also alter the regulation of gene
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mRNA stability. This may result in profound changes in
the signal transduction (reduction in signaling) and
hence produce changes in vascular development [44].
Mice lacking NDP, FZD4, TSPAN12 and LRP5 [45-48]
further demonstrate the importance of wild-type genes
in capillary maturation as well as this pathway in
vasculogenesis and normal retinal development. How-
ever, these transgenic experiments must be interpreted
with caution because, in many patients mutations in
NDP, FZD4, LRP5 and TSPAN12 are missense whereas
in mice models the above four genes are not expressed
(null mutants). Further understanding of this pathway in
ocular disease may lead to a novel therapeutic approach
Figure 2 A highly hypothetical pathway that may lead to a cicatricial ROP and a morphologically similar disorder FEVR. De novo gene
mutation coupled with environmental factors (e. g. prematurity) may lead to the progression and development of retinal detachment in stage 4
- 5 ROP whereas prematurity alone without gene mutation may lead to an early stage of ROP that may subsequently regress to a normal
condition. On the other hand, inherited or de novo mutations without prematurity may result in familial and sporadic FEVR respectively, that
develop during the first decade of life.
Figure 3 A schematic representation of the canonical Wnt signaling pathway. Norrin and Wnt act as ligands to bind FZD4 that interact
with LRP5. In the absence of Wnt signaling, beta-catenin is phosphorylated and subjected to proteosomal degradation. In the presence of Wnt
signaling, beta-catenin accumulates in the cytoplasm and enters the nucleus. Its subsequent interactions with a member of Tcf/Lef family
activate the transcription of Wnt target genes. It was also shown that TSPAN12 is a component of the norrin-LRP5-FZD4 signaling complex and
enhances the levels of norrin-beta-catenin signaling but not Wnt-beta-catenin signaling. Because of mutations in NDP, FZD4, LRP5 and TSPAN12
genes, abnormal signaling may occur which may result in defective Wnt target genes activation that may give rise to FEVR and ROP pathology.
AD = autosomal dominant; AR = autosomal recessive; XL = X-linked recessive; FEVR = familial exudative vitreoretinopathy; ROP = retinopathy of
prematurity; NDP = Norrie disease pseudoglioma.
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the future. However, large-scale studies involving differ-
ent ethnic groups and direct experimental evidence to
show that the same pathway is involved in ROP are
needed to either confirm or refute the above suggestion.
Conclusion
ROP is a leading cause of blindness in children. It is
unknown why some extremely premature babies develop
severe ROP despite timely intervention whereas other
babies with similar clinical characteristics do not pro-
gress to a severe stage. From the foregoing evidence it is
clear that genetic factors in addition to prematurity or
environmental factors play a major role in the develop-
ment and progression of ROP. Identification of poly-
morphisms or mutations in genes is only the beginning
and it may not solve all the problems. We need to con-
sider bioinformatic and proteomic approaches at a given
point in time [24]. A comparison of protein profile
between normal and affected individuals throughout the
c o u r s eo ft h ed i s e a s em a yp r o v i d eab e t t e rd i a g n o s t i c
indicator. For instance, the mutated gene may be under
the control of environmental factors such as oxygen
exposure or prematurity and may not be expressed, over
expressed or change the expression pattern of other
genes. The proteomics approach directly addresses the
status of genes. There are several promising biomarkers
for the risk of ROP. For example, deamination of globin
chains appears to be a promising marker [49]. Addition-
ally, it is possible that ROP involves multiple genes
rather than a single gene, each gene then contributing a
small but additive effect resulting in the final phenotype.
Thus, along with genomics, bioinformatics and proteo-
mics approaches may ultimately provide a better
management of ROP.
Acknowledgements
My apologies for those whose work or original publications could not be
cited in this brief article because of the limitations to the number of
references.
Authors’ contributions
The manuscript was prepared by BSS.
Competing interests
The author declares that they have no competing interests.
Received: 25 June 2010 Accepted: 25 August 2010
Published: 25 August 2010
References
1. Shastry BS: Molecular genetics of Norrie disease, familial exudative
vitreoretinopathy and retinopathy of prematurity. In In retinal
degeneration: causes, diagnosis and treatment. Edited by: Catlin RB. New
York: Nova Science Publishers Inc; 2009:89-106.
2. Good WV, Hardy RJ, Dobson V, Plamer EA, Phelps DL, Quintos M, Tung B:
The incidence and course of retinopathy of prematurity: finding from
the early treatment for retinopathy of prematurity study. Pediatrics 2005,
116:15-23.
3. Terasaki H, Hirose T: Late - onset retinal detachment associated with
regressed retinopathy of prematurity. Jpn J Ophthalmol 2003, 47:492-497.
4. Gilbert WS, Quinn GE, Dobson V, Reynolds J, Hard RJ, Palmer EA: Partial
retinal detachment at 3 months after threshold retinopathy of
prematurity. Arch Ophthalmol 1996, 114:1085-1091.
5. Mechoulam H, Pierce EA: Retinopathy of prematurity. Am J
Pharmacogenomics 2003, 3:261-277.
6. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM: Retinopathy of
prematurity: recent advances in our understanding. Br J Ophthalmol
2002, 86:696-701.
7. Shastry BS: SNPs: impact on gene function and phenotype. Methods Mol
Biol 2009, 578:3-22.
8. Nikopoulos K, Gilissen C, Hoischen A, van Nouhuys CE, Boonstra FN,
Blokland EA, Arts P, Wieskamp N, Strom TM, Ayuso C, Tilanus MA,
Bouwhuis S, Mukhopadhyay A, Scheffer H, Hoefsloot LH, Veltman JA,
Cremers FP, Collin RW: Next generation sequencing of a 40 Mb linkage
interval reveals TSPAN 12 mutations in patients with familial exudative
vitreoretinopathy. Am J Hum Genet 2010, 86:240-247.
9. Poulter JA, Ali M, Gilmour DF, Rice A, Kondo H, Hayashi K, Mackey DA,
Kearns LS, Ruddle JB, Craig JE, Pierce EA, Downey LM, Mohamed MD,
Markham AF, Inglehearn CF, Toomes C: Mutations in TSPAN 12 cause
autosomal dominant familial exudative vitreoretinopathy. Am J Hum
Genet 2010, 86:248-253.
10. Shastry BS, Pendergast D, Hartzer MK, Liu X, Trese MT: Identification of
missense mutations in the Norrie disease gene associated with
advanced retinopathy of prematurity. Arch Ophthalmol 1997, 115:651-656.
11. Dickinson JL, Sale MM, Passmore A, FitzGerald LM, Wheatley CM, Burdon KP,
Craig JE, Tengtrisorn S, Carden SM, Maclean H, Mackey DA: Mutations in
the NDP gene: contribution to Norrie disease, Familial Exudative
Vitreoretinopathy and Retinopathy of Prematurity. Clin Exp Ophthalmol
2006, 34:682-688.
12. Mintz-Hittner HA, Miyashiro MJ, Knight-Nanan KM, O’Malley RE, Marlar RA:
Vitreoretinal findings similar to retinopathy of prematurity in infants
with compound heterozygous protein S deficiency. Ophthalmol 1999,
106:1525-1530.
13. Hiraoka M, Beristein DM, Trese MT, Shastry BS: Insertion and deletion
mutations in the dinucleotide repeat region of the Norrie disease gene
in patients with advanced retinopathy of prematurity. J Hum Genet 2001,
46:178-181.
14. Talks SJ, Ebenezer N, Hykin P, Adams G, Yang F, Schulenberg E, Gregory-
Evans K, Gregory-Evans Y: De novo mutation in the 5′-regulatory region
of the Norrie disease gene in retinopathy of prematurity. J Med Genet
2001, 38:e46.
15. Haider MZ, Devarajan LV, Al-Essa M, Kumar HA: C597A polymorphism in
the Norrie disease gene is associated with advanced retinopathy of
prematurity in Kuwaiti infants. J Biomed Sci 2002, 9:365-370.
16. Haider MZ, Devarajan LV, Al-Essa M, Kumar H: Angiotensin-converting
enzyme gene insertion/deletion polymorphism in Kuwaiti children with
retinopathy of prematurity. Biol Neonate 2002, 82:84-88.
17. Hutcheson KA, Paluru PC, Bernstein SL, Koh J, Rappaport EF, Leach RA,
Young TL: Norrie disease gene sequence variants in an ethnically diverse
population with retinopathy of prematurity. Mol Vis 2005, 11:501-508.
18. MacDonald MLE, Goldberg YP, MacFarlane J, Samuels ME, Trese MT,
Shastry BS: Genetic variants of frizzled-4 gene in familial exudative
vitreoretinopathy and advanced retinopathy of prematurity. Clin Genet
2005, 67:363-366.
19. Ells A, Guemsey DL, Wallace K, Zheng B, Vincer M, Allen A, Ingram A, Da
Silva O, Siebert L, Sheidow T, Beis J, Robitaille JM: Severe retinopathy of
prematurity associated with FZD4 mutations. Ophthalmic Genet 2010,
31:37-43.
20. Bizzarro MJ, Hussain N, Jonsson B, Feng R, Ment LR, Gruen JR, Zhang H,
Bhandari V: Genetic susceptibility to retinopathy of prematurity. Pediatrics
2006, 118:1858-1863.
21. Lang DM, Backledege J, Arnold RW: Is specific race a retinopathy
prematurity risk factor. Arch Pediatr Adolesc Med 2005, 159:771-773.
22. Floyd BN, Leske DA, Wren SM, Mookadam M, Fautsch MP, Holmes JM:
Difference between rat strains in models of retinopathy of prematurity.
Mol Vis 2005, 11:524-530.
Shastry Journal of Biomedical Science 2010, 17:69
http://www.jbiomedsci.com/content/17/1/69
Page 6 of 723. Van Wijngaarden P, Coster DJ, Brereton HM, Gibbins IL, Williams KA: Strain-
dependent differences in oxygen induced retinopathy of prematurity in
the inbred rats. Invest Ophthalmol Vis Sci 2005, 46:1445-1452.
24. Holmstrom G, Van Wijngaarden P, Coster DJ, Williams KA: Genetic
susceptibility to retinopathy of prematurity: the evidence from clinical
and experimental animal studies. Br J Ophthalmol 2007, 97:1704-1708.
25. Pierce EA, Foley ED, Smith LEH: Regulation of Vascular endothelial growth
factor by oxygen in a model of retinopathy of prematurity. Arch
Ophthalmol 1996, 114:1219-1228.
26. Alon T, Hemo I, Itin A, Peer J, Stone J, Keshet E: Vascular endothelial
growth factor acts as a survival factor for newly formed retinal vessels
and has implications for retinopathy of prematurity. Nat Med 1995,
1:1024-1028.
27. Budd SJ, Hartnett ME: Increased angiogenic factors associated with
peripheral avascular retina and intravitreous neovascularization: a model
of retinopathy of prematurity. Arch Ophthalmol 2010, 128:589-595.
28. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE: Identification of
polymorphisms within the vascular endothelial growth factor gene
(VEGF): correlation with variation in VEGF protein production. Cytokine
2000, 12:1232-1235.
29. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E: A
common 936 C/T mutation in the gene for vascular endothelial growth
factor is associated with vascular endothelial growth factor plasma
levels. J Vas Res 2000, 37:443-448.
30. Cooke RW, Drury JA, Mountford R, Clark D: Genetic polymorphisms and
retinopathy of prematurity. Invest Ophthalmol Vis Sci 2004, 45:1712-1715.
31. Vannay AV, Dunai G, Banyasz I, Szabo M, Vamos R, Treszl A, Hajdu J,
Tulassay T, Vasarhel YI: Association of genetic polymorphisms of vascular
endothelial growth factor and risk of proliferative retinopathy of
prematurity. Pediatr Res 2005, 57:396-398.
32. Shastry BS, Qu X: Lack of association of the VEGF gene promoter (-634 G
to C and -460 C to T) polymorphism and the risk of advanced
retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007,
245:741-743.
33. Shastry BS: Lack of association of VEGF (-2578 C to A) and ANG2 (-35 G
to C) gene polymorphisms with the progression of retinopathy of
prematurity. Graefes Arch Clin Exp Ophthalmol 2009, 247:859-860.
34. Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Pietrzyk JJ: The
clinical role of vascular endothelial growth factor (VEGF) system in the
pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp
Ophthalmol 2008, 246:1467-1475.
35. Banyasz I, Bokodl G, Vannay A, Szebenl B, Treszl A, Vasarhelyi B, Tulassay T,
Szabo A: Genetic polymorphisms of vascular endothelial growth factor
and angiopoietin 2 in retinopathy of prematurity. Curr Eye Res 2006,
31:685-690.
36. Dunai G, Vasarhelyi B, Szabo M, Hajdu J, Meszaros G, Tulassay T, Treszl A:
Published genetic variants in retinopathy of prematurity: random forest
analysis suggests a negligible contribution to risk and severity. Curr Eye
Res 2008, 33:501-505.
37. Hellstrom A, Engstrom E, Hard AL, Albertsson-Wildand K, Carlsson B,
Niklasson A, Lofqvist C, Svensson E, Holm S, Ewald U, Holmstrom G,
Smith LE: Postnatal serum insulin-like growth factor - I deficiency is
associated with retinopathy of prematurity and other complications of
premature birth. Pediatrics 2003, 112:1016-1020.
38. Shastry BS: Assessment of the contribution of insulin-like growth factor -I
receptor 3174 G to A polymorphism to the progression of advanced
retinopathy of prematurity. Eur J Ophthalmol 2007, 17:950-953.
39. Balogh A, Derzbach L, Vannay A, Vasarhelyi B: Lack of association between
insulin-like growth factor - I receptor G3174A polymorphism and
retinoapthy of prematurity. Graefes Arch Clin Exp Ophthalmol 2006,
244:1035-1038.
40. Spiegler J, Gilhaus A, Konig IR, Kattner E, Vochem M, Kuster H, Moller J,
Muller D, Kribs A, Segerer H, Weig C, Nikischin W, Van der Wense A,
Gebauer C, Herting E, Gopel W: Polymorphism in the renin-angiotensin
system and outcome of very low birth weight infants. Neonatology 2009,
97:10-14.
41. John BR, Loggins J, Yanamandra K: Angiotensin converting enzyme
insertion/deletion polymorphism does not alter sepsis outcome in
ventilated very low birth weight infants. J Perinatol 2005, 25:205-209.
42. Mohamed S, Schaa K, Cooper ME, Ahrens E, Alvarado A, Colaizy T,
Marazita ML, Murray JC, Dagle JM: Genetic contributions to the
development of retinopathy of prematurity. Pediatr Res 2009, 65:193-197.
43. Ye X, Wang YS, Cahill H, Yu MZ, Badea TC, Smallwood PM, Peachey NS,
Nathans J: Norrin, frizzled 4 and LRP5 signaling in endothelial cells
controls a genetic program for retinal vascularization. Cell 2009,
139:285-298.
44. Qin M, Kondo H, Tahira T, Hayashi K: Moderate reduction of norrin
signaling activity associated with the causative missense mutations
identified in patients with familial exudative vitreoretinopathy. Hum
Genet 2008, 122:615-623.
45. Berger W, Van de Pool D, Bachner D, Oerlemans F, Winkens H, Hameister H,
Wieringa B, Hendricks W, Ropers H-H: An animal model for Norrie disease:
gene targeting of mouse ND gene. Hum Mol Genet 1996, 5:51-59.
46. Wang Y, Huso D, Cahill H, Ruygo D, Nathans J: Progressive cerebellar,
auditory, and esophageal dysfunction caused by targeted disruption of
the frizzled- 4 gene. J Neurosci 2001, 21:4761-4771.
47. Xia CH, Liu H, Cheung D, Wang M, Cheng C, Du X, Chang B, Beutler B,
Gong X: A model for familial exudative vitreoretinopathy caused by
LRP5 mutations. Hum Mol Genet 2008, 17:1605-1612.
48. Junge HJ, Yang S, Burton JR, Paes K, Shu X, French DM, Costa M, Rice DS,
Ye W: TSPAN12 regulates retinal vascular development by promoting
norrin but not Wnt induced FZD4/beta-catenin signaling. Cell 2009,
139:299-311.
49. Madan A, El-Ferzli G, Carlson SM, Whitin JC, Schilling J, Najmi A, Yu TT,
Lau K, Dimmitt RA, Cohen HJ: A potential biomarker in the cord blood of
preterm infants who develop retinopathy of prematurity. Pediatr Res
2007, 61:215-221.
doi:10.1186/1423-0127-17-69
Cite this article as: Shastry: Genetic susceptibility to advanced
retinopathy of prematurity (ROP). Journal of Biomedical Science 2010
17:69.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Shastry Journal of Biomedical Science 2010, 17:69
http://www.jbiomedsci.com/content/17/1/69
Page 7 of 7